BioCryst Pharmaceuticals, Inc.
NASDAQ:BCRX
Overview | Financials
| Company Name | BioCryst Pharmaceuticals, Inc. |
| Symbol | BCRX |
| Currency | USD |
| Price | 8.19 |
| Market Cap | 1,719,244,800 |
| Dividend Yield | 0% |
| 52-week-range | 6.02 - 11.31 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Mr. Jon P. Stonehouse |
| Website | https://www.biocryst.com |
An error occurred while fetching data.
About BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD



